Search

Sarepta Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

18.1 -1.79

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.63

Max

18.41

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.9M

326M

Pārdošana

-330M

401M

P/E

Sektora vidējais

42.919

57.002

EPS

0.42

Peļņas marža

81.263

Darbinieki

835

EBITDA

-345M

30M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+22.86% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 2. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

138M

1.8B

Iepriekšējā atvēršanas cena

19.89

Iepriekšējā slēgšanas cena

18.1

Ziņu noskaņojums

By Acuity

80%

20%

322 / 340 Rangs Healthcare

Sarepta Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

2026. g. 13. aug. 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

2026. g. 12. aug. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

2026. g. 11. aug. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

2026. g. 10. aug. 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

2026. g. 7. aug. 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

2026. g. 6. aug. 20:03 UTC

Social Media
News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

2026. g. 5. aug. 23:11 UTC

News
Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

2026. g. 4. aug. 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

2026. g. 3. aug. 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

2026. g. 30. jūl. 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

2026. g. 29. jūl. 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

2026. g. 28. jūl. 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

2026. g. 27. jūl. 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

2026. g. 21. jūl. 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Salīdzinājums

Cenas izmaiņa

Sarepta Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

22.86% augšup

Prognoze 12 mēnešiem

Vidējais 22.63 USD  22.86%

Augstākais 38 USD

Zemākais 5 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sarepta Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

17 ratings

5

Pirkt

8

Turēt

4

Pārdot

Noskaņojums

By Acuity

322 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat